Opinion
Video
Exploring Therapeutic Avenues in HER2+ Breast Cancer
Experts delve into post–KATHERINE trial discussions, examining data and its impact on residual disease. They highlight unmet needs, emphasizing the ongoing CompassHER2 RD trial’s potential to address challenges, especially regarding brain metastases.
This is a video synopsis/summary of a Peer Exchange involving Joyce O’Shaughnessy, MD; Priyanka Sharma, MD; Claudine Isaacs, MD; Heather McArthur, MD; and Hope S. Rugo, MD, FASCO.
O’Shaughnessy and Rugo discuss the potential of neratinib in addressing residual disease after T-DM1 treatment in patients with HER2-positive breast cancer. The external study showed positive results, especially in patients who are estrogen-receptor positive, highlighting the need for additional therapies to prevent metastasis. O’Shaughnessy acknowledges the ongoing CompassHER2 RD trial’s aim to reduce the risk of brain metastasis by combining T-DM1 (trastuzumab emtansine) with tucatinib. Isaacs stresses the importance of enrolling patients in trials targeting brain metastases, aiming for better standards of care. The discussion emphasizes the optimization of endocrine therapy for HER2-positive patients and ongoing efforts to improve treatment strategies in both adjuvant and metastatic settings.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
Latest CME
View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Jun 6th 2025 - Jul 12th 2025
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Jun 6th 2025 - Jul 12th 2025
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Jun 5th 2025 - Jul 12th 2025
